fluticasone furoate/vilanterol vs fluticasone propionate
Same mechanism, same race: design-graded trial evidence for both assets, with the grading rationale shown. Grades describe the quality of the evidence, never the merits of either security.
Asthma
Shared mechanism: Glucocorticoid receptor · full Asthma pipeline
fluticasone furoate/vilanterol · Breo Ellipta
Marketed by GlaxoSmithKline
NCT01086384 · Phase 3 · completed
This was a randomized, triple-blind, active-controlled trial with approximately 2,019 treated participants. Its primary hard clinical endpoint—having one or more severe asthma exacerbations—favored fluticasone furoate/vilanterol and was statistically significant.
Reported efficacy
Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): Number of Participants With 1 or More Severe Asthma Exacerbations (Baseline to Follow-up (up to 76 weeks of treatment)): FF/VI 100/25 µg 154/1009 vs FF 100 µg 186/1010 (met)
Result source: NCT01086384
fluticasone propionate
Marketed by GlaxoSmithKline
No graded featured trial for this indication yet; the grade above reflects that absence, not a judgment.
Next expected readout: September 2027 · NCT07664527 (registry estimate)
No aligned efficacy figure on record for this race.
Results for Asthma
Values come from each drug's own ClinicalTrials.gov study. They are from separate trials and patient populations, not a head-to-head comparison. Each result identifies its source trial, phase, arm and timepoint; limitations that apply to a whole cell are marked with a letter and listed once beneath the table. The comparison is deepest for later-stage drugs (phase 3 or approved), which usually have posted results to draw on; early-stage drugs often have none yet.
| Key endpoint | fluticasone furoate/vilanterol | fluticasone propionate |
|---|---|---|
| Severe exacerbations, annualised rate | —Trial running · NCT05757102 | 1.9 vs 2.1vs Fluticasone PropionateNCT004526991 other result
|
| Trough FEV1, change | 0.4 vs 0.2+0.2 vs placeboNCT011651388 other results
| 0.2 vs 0.1+0.2 vs placeboNCT0213964425 other results
|
| ACQ-5, change | -1.2 vs -1.1vs FFNCT032481281 other result
| —Not posted · NCT00158834 |
| OCS dose reduction | —Trial running · NCT05757102 | —Not posted · NCT00158834 |
Severe exacerbations, annualised rate
- fluticasone furoate/vilanterol
- —Trial running · NCT05757102
- fluticasone propionate
- 1.9 vs 2.1vs Fluticasone PropionateNCT00452699
1 other result
- 2.6 vs 2.7 NCT00452348
Trough FEV1, change
- fluticasone furoate/vilanterol
- 0.4 vs 0.2+0.2 vs placeboNCT01165138
8 other results
- 0.4 vs 0.2 NCT01134042
- 0.5 vs 0.4 NCT01686633
- 0.3 vs 0.3 NCT01147848
- -0.1 vs -0.1 NCT02094937
- 0.4 vs 0.4 NCT01686633
- 0.3 vs 0.3 NCT01086384
- 0.3 vs 0.3 NCT03248128
- 0.3 vs 0.2 NCT03248128
- fluticasone propionate
- 0.2 vs 0.1+0.2 vs placeboNCT02139644
25 other results
- 0.2 vs 0.1 NCT02139644
- 0.1 vs 0.0 NCT02175771
- 0.1 vs 0.0 NCT02175771
- -0.1 vs -0.1 NCT02094937
- 0.1 vs 0.0 NCT02175771
- 0.1 vs 0.0 NCT02175771
- 0.1 vs 0.1 NCT01576718
- 0.1 vs 0.1 NCT01576718
- 0.3 vs 0.1 NCT01479621
- 0.1 vs 0.1 NCT01576718
- 0.2 vs 0.1 NCT01479621
- 0.1 vs 0.1 NCT01576718
- 0.2 vs 0.1 NCT01479621
- 0.2 vs 0.1 NCT01479621
- 0.2 vs 0.1 NCT00452348
- 0.1 vs 0.1 NCT01576718
- 0.2 vs 0.1 NCT01563029
- 0.1 vs 0.1 NCT01576718
- 0.1 vs 0.1 NCT01563029
- 0.1 vs 0.1 NCT01576718
- 0.1 vs 0.1 NCT01576718
- 0.3 vs 0.1 NCT01563029
- 0.2 vs 0.2 NCT01573767
- 0.2 vs 0.2 NCT01573767
- 0.2 vs 0.2 NCT01573767
ACQ-5, change
- fluticasone furoate/vilanterol
- -1.2 vs -1.1vs FFNCT03248128
1 other result
- -1.3 vs -1.1 NCT03248128
- fluticasone propionate
- —Not posted · NCT00158834
OCS dose reduction
- fluticasone furoate/vilanterol
- —Trial running · NCT05757102
- fluticasone propionate
- —Not posted · NCT00158834
- Each cell is from that drug's own trial. Trials differ in population, design and timepoint; this is not a head-to-head comparison.
- An empty cell names why: Not posted (a completed Phase 3 here has no posted results yet), Trial running, Pending review (we hold the result and are checking it) or Not reported.
15 other shared endpoints and safety
Coverage. fluticasone furoate/vilanterol: 19 of 19 rows · fluticasone propionate: 19 of 19 rows. A dash means no reviewed, structured value is available for that endpoint in this indication.
| Reported metric | fluticasone furoate/vilanterol Rows use multiple source trials | fluticasone propionate Rows use multiple source trials |
|---|---|---|
| ACT Control responder rate · % of participants | 92% (n=471) vs 93% (n=467) FP/S @ 24wk100/25 mcg Once Dailya,b NCT02301975 · Phase 3 · registry result, not featured evidence | 92% (n=471) vs 93% (n=467) FP/S @ 24wk100/25 mcg Once Dailya,b NCT02301975 · Phase 3 · registry result, not featured evidence |
| ACT Total absolute change · score | -0.3 vs -0.6 FP 100 mcg BD score @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence | -0.3 vs -0.6 FP 100 mcg BD score @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence |
| AM PEF Change L/Min absolute change · L/min | 8.9 vs 3.7 FP/S L/min @ 24wk100/25 mcg Once Dailya,b NCT02301975 · Phase 3 · registry result, not featured evidence | 8.9 vs 3.7 FP/S L/min @ 24wk100/25 mcg Once Dailya,b NCT02301975 · Phase 3 · registry result, not featured evidence |
| Evening PEF absolute change · L/min | 26.4 vs -1.8 placebo L/min @ 12wk100/25 µg ODc,d,b NCT01165138 · Phase 3 2 other source trials39.7 vs 15.5 FF L/min @ 12wk100/25 µg OD NCT01686633 · Phase 3 41.7 vs 15.5 FF L/min @ 12wk200/25 µg OD NCT01686633 · Phase 3 | 13.5 vs 5.1 placebo L/min @ 12wk100 µg ODe,c,d,b NCT01563029 · Phase 2 · registry result, not featured evidence show 5 more doses11 vs 5 placebo L/min @ 12wk100 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 18.5 vs 5.1 placebo L/min @ 12wk50 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 18.2 vs 5 placebo L/min @ 12wk50 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 16.3 vs 5.1 placebo L/min @ 12wk25 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 16.2 vs 5 placebo L/min @ 12wk25 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence |
| Evening PEF absolute change · L | 39.2 vs -11.8 placebo L @ 12wk100/25 µg Once Dailyc,a,b NCT01498679 · Phase 3 · registry result, not featured evidence 1 other source trial39.1 vs 10.5 Fluticasone Propionate L200/25 µg Once Daily NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 | 7.45 vs 3.42 placebo L @ 12wk200 mcge,c,a,b NCT01576718 · Phase 2 · registry result, not featured evidence show 7 more doses7.89 vs 3.35 placebo L @ 12wk200 mcg NCT01576718 · Phase 2 · registry result, not featured evidence 6.41 vs 3.42 placebo L @ 12wk100 mcg NCT01576718 · Phase 2 · registry result, not featured evidence 6.52 vs 3.35 placebo L @ 12wk100 mcg NCT01576718 · Phase 2 · registry result, not featured evidence 3.81 vs 3.42 placebo L @ 12wk50 mcg NCT01576718 · Phase 2 · registry result, not featured evidence 4.22 vs 3.35 placebo L @ 12wk50 mcg NCT01576718 · Phase 2 · registry result, not featured evidence 10.97 vs 3.42 placebo L @ 12wk400 mcg NCT01576718 · Phase 2 · registry result, not featured evidence 11.72 vs 3.35 placebo L @ 12wk400 mcg NCT01576718 · Phase 2 · registry result, not featured evidence |
| Evening PEF Change L/Min absolute change · L/min | 5.5 vs 0.5 FP/S L/min @ 24wk100/25 mcg Once Dailya,b NCT02301975 · Phase 3 · registry result, not featured evidence | 5.5 vs 0.5 FP/S L/min @ 24wk100/25 mcg Once Dailya,b NCT02301975 · Phase 3 · registry result, not featured evidence |
| FEV1 absolute change · L | 0.019 vs 0 FP/S L @ 24wk100/25 mcg Once Dailye,a,b NCT02301975 · Phase 3 · registry result, not featured evidence show 1 more dose0.02 vs 0.014 FP/S L @ 24wk100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence | 0.019 vs 0 FP/S L @ 24wk100/25 mcg Once Dailye,a,b NCT02301975 · Phase 3 · registry result, not featured evidence show 1 more dose0.02 vs 0.014 FP/S L @ 24wk100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence |
| Max Post-exercise FEV1 Fall percent change · % of baseline | 15.02% (n=70) vs 16.71% (n=69) FP @ 2wk100/25 µg QDe,a,b NCT02730351 · Phase 4 · registry result, not featured evidence show 1 more dose11.9% (n=68) vs 14.05% (n=69) FP @ 2wk100/25 µg QD NCT02730351 · Phase 4 · registry result, not featured evidence | 15.02% (n=70) vs 16.71% (n=69) FP @ 2wk100/25 µg QDe,a,b NCT02730351 · Phase 4 · registry result, not featured evidence show 1 more dose11.9% (n=68) vs 14.05% (n=69) FP @ 2wk100/25 µg QD NCT02730351 · Phase 4 · registry result, not featured evidence |
| Morning PEF absolute change · L/min | 14.9 vs 9.3 FF L/min @ 12wke,c,a,b NCT03248128 · Phase 3 · Asthma · phase 3 show 1 more dose11.9 vs 8.9 FF L/min @ 12wk NCT03248128 · Phase 3 · Asthma · phase 3 | 15.8 vs 3.3 placebo L/min @ 12wk100 µg ODe,c,a,b NCT01563029 · Phase 2 · registry result, not featured evidence show 5 more doses14.2 vs 2.7 placebo L/min @ 12wk100 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 22.8 vs 3.3 placebo L/min @ 12wk50 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 20.6 vs 2.7 placebo L/min @ 12wk50 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 21.9 vs 3.3 placebo L/min @ 12wk25 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 23.3 vs 2.7 placebo L/min @ 12wk25 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence |
| Poorly-controlled Asthma Withdrawal responder rate · % of participants | 4.9% (n=123) vs 7.3% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence | 4.9% (n=123) vs 7.3% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence |
| Rescue-free 24 h Periods absolute change · percentage points | -0.9% (n=122) vs -2.1% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence | -0.9% (n=122) vs -2.1% (n=124) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence |
| Rescue-free 24-h Period percent change · % of baseline | -3% (n=500) vs -4.2% (n=498) FP/S @ 24wk100/25 mcg Once Dailya,b NCT02301975 · Phase 3 · registry result, not featured evidence | -3% (n=500) vs -4.2% (n=498) FP/S @ 24wk100/25 mcg Once Dailya,b NCT02301975 · Phase 3 · registry result, not featured evidence |
| Symptom-free 24 h Periods absolute change · percentage points | -3.5% (n=500) vs -4.7% (n=498) FP/S @ 24wk100/25 mcg Once Dailya,b NCT02301975 · Phase 3 · registry result, not featured evidence | -3.5% (n=500) vs -4.7% (n=498) FP/S @ 24wk100/25 mcg Once Dailya,b NCT02301975 · Phase 3 · registry result, not featured evidence |
| Symptom-free 24-h Period percent change · % of baseline | 32.5% (n=201) vs 14.6% (n=202) placebo @ 12wk100/25 µg ODc,a,b,f NCT01165138 · Phase 3 3 other source trials27.2% (n=345) vs 19.4% (n=346) FF @ 12wk100/25 µg OD NCT01686633 · Phase 3 29% (n=346) vs 19.4% (n=346) FF @ 12wk200/25 µg OD NCT01686633 · Phase 3 24.8% (n=153) vs 9% (n=154) placebo @ 12wk100/25 µg Once Daily NCT01498679 · Phase 3 · registry result, not featured evidence | 19.7% (n=110) vs 9.9% (n=113) placebo @ 4wk25 µg ODe,c,a,b,f NCT01573767 · Phase 2 · registry result, not featured evidence show 2 more doses18.3% (n=112) vs 9.9% (n=113) placebo @ 4wk12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 10.1% (n=113) vs 9.9% (n=113) placebo @ 4wk6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence |
| Well Controlled Asthma responder rate · % of participants | 89.5% (n=114) vs 78.2% (n=119) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence | 89.5% (n=114) vs 78.2% (n=119) FP 100 mcg BD @ 20wk100 mcg once dailya,b NCT02094937 · Phase 3 · registry result, not featured evidence |
| Dropout rate | —100/25 µgg NCT01086384 · Phase 3 show 16 more results—200/25 µg OD NCT01018186 · Phase 3 —100/25 µg OD NCT01018186 · Phase 3 — NCT03248128 · Phase 3 · Asthma · phase 3 10.9%100/25 µg OD NCT01165138 · Phase 3 7.2%200/25 µg OD NCT01686633 · Phase 3 9.2%100/25 µg OD NCT01686633 · Phase 3 14.2%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 —100/25 µg OD NCT01147848 · Phase 3 · Asthma · phase 3 —100/25 µg QD NCT02730351 · Phase 4 · registry result, not featured evidence 6.2%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 14.4%100/25 µg Once Daily NCT01498679 · Phase 3 · registry result, not featured evidence 12.3%200/25 µg Once Daily NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 —100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence | —100/25 µg QDh NCT02730351 · Phase 4 · registry result, not featured evidence show 41 more results—50 ug, 1.5 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 1.5 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 3 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 3 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 6 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 6 um NCT00692978 · Phase 4 · registry result, not featured evidence 53.1%Asthmatic Smoker Treated With Mont NCT00712335 · Phase 4 · registry result, not featured evidence 37.5%Asthmatic Smokers Treated With Com NCT00712335 · Phase 4 · registry result, not featured evidence · combination 26.5%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence 25.5%250/50 mcg BID NCT00452348 · Phase 4 · registry result, not featured evidence —50/100 mcg BD NCT00353873 · Phase 4 · registry result, not featured evidence —100/50mcg BID NCT00118716 · Phase 4 · registry result, not featured evidence 2.8%50/12.5 mcg BID NCT02980133 · Phase 3 · registry result, not featured evidence 6.2%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —100 mcg NCT02139644 · Phase 3 · registry result, not featured evidence —50 mcg NCT02139644 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination —200/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —200 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100/50 HFA NCT00441441 · Phase 3 · registry result, not featured evidence 28%100 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 27.5%50 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 20.3%25 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 21.1%25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 12.4%12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 18.4%6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —12.5 OD NCT01573767 · Phase 2 · registry result, not featured evidence —25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —6.25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —200 mcg NCT01576718 · Phase 2 · registry result, not featured evidence —100 mcg NCT01576718 · Phase 2 · registry result, not featured evidence —50 mcg NCT01576718 · Phase 2 · registry result, not featured evidence —400 mcg NCT01576718 · Phase 2 · registry result, not featured evidence —100 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —50 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —25 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —12.5 mcg NCT01479621 · Phase 2 · registry result, not featured evidence |
| Discontinued due to AEs | —100/25 µgg NCT01086384 · Phase 3 show 16 more results—200/25 µg OD NCT01018186 · Phase 3 —100/25 µg OD NCT01018186 · Phase 3 — NCT03248128 · Phase 3 · Asthma · phase 3 1%100/25 µg OD NCT01165138 · Phase 3 0.9%200/25 µg OD NCT01686633 · Phase 3 0.9%100/25 µg OD NCT01686633 · Phase 3 3.6%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 —100/25 µg OD NCT01147848 · Phase 3 · Asthma · phase 3 —100/25 µg QD NCT02730351 · Phase 4 · registry result, not featured evidence 1.6%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 2.6%100/25 µg Once Daily NCT01498679 · Phase 3 · registry result, not featured evidence 1.3%200/25 µg Once Daily NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 —100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence | —100/25 µg QDh NCT02730351 · Phase 4 · registry result, not featured evidence show 41 more results—50 ug, 1.5 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 1.5 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 3 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 3 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 6 um NCT00692978 · Phase 4 · registry result, not featured evidence —50 ug, 6 um NCT00692978 · Phase 4 · registry result, not featured evidence —Asthmatic Smoker Treated With Mont NCT00712335 · Phase 4 · registry result, not featured evidence —Asthmatic Smokers Treated With Com NCT00712335 · Phase 4 · registry result, not featured evidence · combination 3.3%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence 1.9%250/50 mcg BID NCT00452348 · Phase 4 · registry result, not featured evidence —50/100 mcg BD NCT00353873 · Phase 4 · registry result, not featured evidence —100/50mcg BID NCT00118716 · Phase 4 · registry result, not featured evidence —50/12.5 mcg BID NCT02980133 · Phase 3 · registry result, not featured evidence 1.6%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —100 mcg NCT02139644 · Phase 3 · registry result, not featured evidence —50 mcg NCT02139644 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence —100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination —200/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —200 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100 mcg NCT02175771 · Phase 3 · registry result, not featured evidence —100/50 HFA NCT00441441 · Phase 3 · registry result, not featured evidence 1.7%100 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 0.8%50 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 0%25 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 0.9%25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 0.9%6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —12.5 OD NCT01573767 · Phase 2 · registry result, not featured evidence —25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —6.25 OD NCT01573767 · Phase 2 · registry result, not featured evidence —200 mcg NCT01576718 · Phase 2 · registry result, not featured evidence —100 mcg NCT01576718 · Phase 2 · registry result, not featured evidence —50 mcg NCT01576718 · Phase 2 · registry result, not featured evidence —400 mcg NCT01576718 · Phase 2 · registry result, not featured evidence —100 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —50 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —25 mcg NCT01479621 · Phase 2 · registry result, not featured evidence —12.5 mcg NCT01479621 · Phase 2 · registry result, not featured evidence |
| Serious AEs | 4.1%100/25 µgg NCT01086384 · Phase 3 show 16 more results0.5%200/25 µg OD NCT01018186 · Phase 3 1.5%100/25 µg OD NCT01018186 · Phase 3 1.1% NCT03248128 · Phase 3 · Asthma · phase 3 0%100/25 µg OD NCT01165138 · Phase 3 0.3%200/25 µg OD NCT01686633 · Phase 3 1.2%100/25 µg OD NCT01686633 · Phase 3 3%200/25 µg OD NCT01134042 · Phase 3 · combination · Asthma · phase 3 1%100/25 µg OD NCT01147848 · Phase 3 · Asthma · phase 3 1.4%100/25 µg QD NCT02730351 · Phase 4 · registry result, not featured evidence 1.2%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence 0.8%100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence 0%100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 1.3%100/25 µg Once Daily NCT01498679 · Phase 3 · registry result, not featured evidence 0.6%200/25 µg Once Daily NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 0%100 µg/25 µg NCT01453023 · Phase 2 · registry result, not featured evidence | 1.4%100/25 µg QDh NCT02730351 · Phase 4 · registry result, not featured evidence show 41 more results0%50 ug, 1.5 um NCT00692978 · Phase 4 · registry result, not featured evidence 0%50 ug, 1.5 um NCT00692978 · Phase 4 · registry result, not featured evidence 0%50 ug, 3 um NCT00692978 · Phase 4 · registry result, not featured evidence 0%50 ug, 3 um NCT00692978 · Phase 4 · registry result, not featured evidence 0%50 ug, 6 um NCT00692978 · Phase 4 · registry result, not featured evidence 0%50 ug, 6 um NCT00692978 · Phase 4 · registry result, not featured evidence 0%Asthmatic Smoker Treated With Mont NCT00712335 · Phase 4 · registry result, not featured evidence 0%Asthmatic Smokers Treated With Com NCT00712335 · Phase 4 · registry result, not featured evidence · combination 4.6%250/50 mcg BID NCT00452699 · Phase 4 · registry result, not featured evidence 2.3%250/50 mcg BID NCT00452348 · Phase 4 · registry result, not featured evidence 2%50/100 mcg BD NCT00353873 · Phase 4 · registry result, not featured evidence 0%100/50mcg BID NCT00118716 · Phase 4 · registry result, not featured evidence 1.9%50/12.5 mcg BID NCT02980133 · Phase 3 · registry result, not featured evidence 1.2%100/25 mcg Once Daily NCT02301975 · Phase 3 · registry result, not featured evidence 0.8%100 mcg NCT02139644 · Phase 3 · registry result, not featured evidence 0%50 mcg NCT02139644 · Phase 3 · registry result, not featured evidence —100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence 0.8%100 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence 0%100/25 mcg once daily NCT02094937 · Phase 3 · registry result, not featured evidence · combination 9.8%200/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 6.4%200 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 5%100/12.5 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 5.5%100 mcg NCT02175771 · Phase 3 · registry result, not featured evidence 0.6%100/50 HFA NCT00441441 · Phase 3 · registry result, not featured evidence 0.8%100 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 0.8%50 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence 0%25 µg OD NCT01563029 · Phase 2 · registry result, not featured evidence —25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —12.5 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence —6.25 µg OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%12.5 OD NCT01573767 · Phase 2 · registry result, not featured evidence 0.9%25 OD NCT01573767 · Phase 2 · registry result, not featured evidence 0%6.25 OD NCT01573767 · Phase 2 · registry result, not featured evidence 0.9%200 mcg NCT01576718 · Phase 2 · registry result, not featured evidence 0.9%100 mcg NCT01576718 · Phase 2 · registry result, not featured evidence 0.9%50 mcg NCT01576718 · Phase 2 · registry result, not featured evidence 0%400 mcg NCT01576718 · Phase 2 · registry result, not featured evidence 1.9%100 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 1%50 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 0%25 mcg NCT01479621 · Phase 2 · registry result, not featured evidence 0%12.5 mcg NCT01479621 · Phase 2 · registry result, not featured evidence |
| Most frequent reported AEs | 100/25 µgg headache 18.6% nasopharyngitis 15.4% upper respiratory tract infection 7.2% NCT01086384 · Phase 3 show 15 more results200/25 µg OD headache 17.3% upper respiratory tract infection 14.9% nasopharyngitis 9.4% NCT01018186 · Phase 3 100/25 µg OD headache 19.4% upper respiratory tract infection 16.9% nasopharyngitis 12.4% NCT01018186 · Phase 3 nasopharyngitis 10.4% upper respiratory tract infection 7% rhinitis allergic 4.2% NCT03248128 · Phase 3 · Asthma · phase 3 200/25 µg OD headache 8.4% nasopharyngitis 7.2% upper respiratory tract infection 2% NCT01686633 · Phase 3 100/25 µg OD headache 8.4% nasopharyngitis 6.4% upper respiratory tract infection 2.3% NCT01686633 · Phase 3 200/25 µg OD nasopharyngitis 12.7% headache 5.6% bronchitis 3.6% NCT01134042 · Phase 3 · combination · Asthma · phase 3 100/25 µg OD nasopharyngitis 11.4% headache 8.4% upper respiratory tract infection 6.2% NCT01147848 · Phase 3 · Asthma · phase 3 100/25 µg QD upper respiratory tract infection 6.8% NCT02730351 · Phase 4 · registry result, not featured evidence 100/25 mcg Once Daily nasopharyngitis 12.1% headache 8.1% bronchitis 4% NCT02301975 · Phase 3 · registry result, not featured evidence 100 mcg once daily nasopharyngitis 17.9% NCT02094937 · Phase 3 · registry result, not featured evidence 100/25 mcg once daily nasopharyngitis 15.6% NCT02094937 · Phase 3 · registry result, not featured evidence · combination 100/25 µg Once Daily upper respiratory tract infection 7.2% (placebo 9.1%) headache 4.6% (placebo 1.9%) nasopharyngitis 4.6% (placebo 8.4%) NCT01498679 · Phase 3 · registry result, not featured evidence 200/25 µg Once Daily upper respiratory tract infection 8.4% nasopharyngitis 3.9% rhinitis allergic 3.2% NCT01498653 · Phase 3 · registry result, not featured evidence · Asthma · phase 3 100 µg/25 µg bronchitis 4% conjunctivitis 4% headache 4% NCT01453023 · Phase 2 · registry result, not featured evidence | 100/25 µg QDh upper respiratory tract infection 6.8% NCT02730351 · Phase 4 · registry result, not featured evidence show 29 more results250/50 mcg BID upper respiratory tract infection 20.3% headache 18.3% nasopharyngitis 17.6% NCT00452699 · Phase 4 · registry result, not featured evidence 250/50 mcg BID nasopharyngitis 17.4% headache 16.5% upper respiratory tract infection 14.5% NCT00452348 · Phase 4 · registry result, not featured evidence 50/100 mcg BD headache 18% nasopharyngitis 9.3% rhinitis 8% NCT00353873 · Phase 4 · registry result, not featured evidence 100/50mcg BID headache 3.2% upper respiratory tract infection 3.2% abdominal pain upper 2.4% NCT00118716 · Phase 4 · registry result, not featured evidence 50/12.5 mcg BID nasopharyngitis 4.3% (placebo 5.3%) NCT02980133 · Phase 3 · registry result, not featured evidence 100/25 mcg Once Daily nasopharyngitis 12.1% headache 8.1% bronchitis 4% NCT02301975 · Phase 3 · registry result, not featured evidence 100 mcg headache 7% (placebo 3.9%) nasopharyngitis 7% (placebo 3.1%) upper respiratory tract infection 3.1% (placebo 4.7%) NCT02139644 · Phase 3 · registry result, not featured evidence 50 mcg nasopharyngitis 5.4% (placebo 3.1%) upper respiratory tract infection 5.4% (placebo 4.7%) headache 1.6% (placebo 3.9%) NCT02139644 · Phase 3 · registry result, not featured evidence 100 mcg once daily nasopharyngitis 17.9% NCT02094937 · Phase 3 · registry result, not featured evidence 100/25 mcg once daily nasopharyngitis 15.6% NCT02094937 · Phase 3 · registry result, not featured evidence · combination 200/12.5 mcg upper respiratory tract infection 18% sinusitis 10.5% nasopharyngitis 9% NCT02175771 · Phase 3 · registry result, not featured evidence 200 mcg upper respiratory tract infection 13.6% cough 10.4% nasopharyngitis 10.4% NCT02175771 · Phase 3 · registry result, not featured evidence 100/12.5 mcg upper respiratory tract infection 17.5% nasopharyngitis 12.5% cough 11.7% NCT02175771 · Phase 3 · registry result, not featured evidence 100 mcg upper respiratory tract infection 18.1% nasopharyngitis 13.4% sinusitis 11.8% NCT02175771 · Phase 3 · registry result, not featured evidence 100/50 HFA headache 15% nasopharyngitis 9.2% upper respiratory tract infection 6.4% NCT00441441 · Phase 3 · registry result, not featured evidence 100 µg OD cough 8.5% (placebo 5%) headache 5.9% (placebo 1.7%) rhinorrhoea 5.1% (placebo 1.7%) NCT01563029 · Phase 2 · registry result, not featured evidence 50 µg OD pharyngitis 5.8% (placebo 3.4%) bronchitis 3.3% (placebo 0.8%) nasopharyngitis 3.3% (placebo 3.4%) NCT01563029 · Phase 2 · registry result, not featured evidence 25 µg OD nasopharyngitis 7.6% (placebo 3.4%) cough 5.9% (placebo 5%) oropharyngeal pain 5.1% (placebo 0.8%) NCT01563029 · Phase 2 · registry result, not featured evidence 12.5 OD nasopharyngitis 8.8% (placebo 7%) headache 1.8% (placebo 3.5%) influenza 0% (placebo 0%) NCT01573767 · Phase 2 · registry result, not featured evidence 25 OD nasopharyngitis 7.9% (placebo 7%) headache 1.8% (placebo 3.5%) influenza 0% (placebo 0%) NCT01573767 · Phase 2 · registry result, not featured evidence 6.25 OD nasopharyngitis 7% (placebo 7%) headache 5.3% (placebo 3.5%) influenza 3.5% (placebo 0%) NCT01573767 · Phase 2 · registry result, not featured evidence 100 mcg upper respiratory tract infection 4.9% (placebo 2.9%) nasopharyngitis 2.9% (placebo 4.8%) NCT01479621 · Phase 2 · registry result, not featured evidence 50 mcg nasopharyngitis 6.7% (placebo 4.8%) upper respiratory tract infection 2.9% (placebo 2.9%) NCT01479621 · Phase 2 · registry result, not featured evidence 25 mcg nasopharyngitis 4.8% (placebo 4.8%) upper respiratory tract infection 1.9% (placebo 2.9%) NCT01479621 · Phase 2 · registry result, not featured evidence 12.5 mcg upper respiratory tract infection 6.8% (placebo 2.9%) nasopharyngitis 3.9% (placebo 4.8%) NCT01479621 · Phase 2 · registry result, not featured evidence |
Notes
- aPopulation comparability has not been reviewed for both studies.
- bTreatment context has not been resolved for both arms.
- cTrial phases differ: Phase 2 versus Phase 3.
- dPopulation context differs: age eligibility differs (includes children versus adolescents and adults).
- eThis study reports multiple eligible drug arms; no representative arm has been reviewed.
- fAssessment timepoints differ: 4 weeks versus 12 weeks.
- gPopulation comparability has not been reviewed for 13 of these studies.
- hPopulation comparability has not been reviewed for these studies.
Reported by one asset only
Endpoints only one of the selected assets measured, so there is nothing to compare them against.
fluticasone furoate/vilanterol
show 1 more result
show 1 more result
show 1 more result
show 1 more result
show 3 more results
show 4 more results
+ 3 further endpoints in the CSV export.
fluticasone propionate
show 1 more result
show 1 more result
show 12 more results
show 4 more results
show 6 more results
+ 16 further endpoints in the CSV export.
The full competitive landscape for each asset (every same-race competitor with aligned evidence, sortable) is on the asset pages: fluticasone furoate/vilanterol's landscape · fluticasone propionate's landscape